Schiöth Helgi B, Boström Adrian, Murphy Susan K, Erhart Wiebke, Hampe Jochen, Moylan Cynthia, Mwinyi Jessica
Department of Neuroscience, Division of Functional Pharmacology, Uppsala University, Uppsala, Sweden.
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
BMC Genomics. 2016 Jun 14;17:462. doi: 10.1186/s12864-016-2814-z.
Non-alcoholic fatty liver disease (NAFLD) is associated with a high risk for liver cirrhosis and cancer. Recent studies demonstrate that NAFLD significantly impacts on the genome wide methylation and expression reporting top hit genes to be associated with e.g. diabetes mellitus. In a targeted analysis we specifically investigate to what extent NAFLD is associated with methylation and transcriptional changes in gene networks responsible for drug metabolism (DM) and bile acid (BA) homeostasis, which may trigger liver and system toxic events.
We performed a systematic analysis of 73 genes responsible for BA homeostasis and DM based on liver derived methylation and expression data from three cohort studies including 103 NAFLD and 75 non-NAFLD patients. Using multiple linear regression models, we detected methylation differences in proximity to the transcriptional start site of these genes in two NAFLD cohorts and correlated the methylation of significantly changed CpG sites to transcriptional expression in a third cohort using robust multiple linear regression approaches.
We detected 64 genes involved in BA homeostasis and DM to be significantly differentially methylated. In 26 of these genes, methylation significantly correlated with RNA expression, detecting i.e. genes such as CYP27A1, OSTɑ, and SLC27A5 (BA homeostasis), and SLCO2B1, SLC47A1, and several UGT and CYP genes (DM) to be NAFLD dependently modulated.
NAFLD is associated with significant shifts in the methylation of key genes responsible for BA and DM that are associated with transcriptional modulations. These findings have implications for BA composition, BA regulated metabolic pathways and for drug safety and efficacy.
非酒精性脂肪性肝病(NAFLD)与肝硬化和癌症的高风险相关。最近的研究表明,NAFLD对全基因组甲基化和表达有显著影响,报告的热门基因与例如糖尿病相关。在一项针对性分析中,我们专门研究了NAFLD在多大程度上与负责药物代谢(DM)和胆汁酸(BA)稳态的基因网络中的甲基化和转录变化相关,这可能引发肝脏和全身毒性事件。
我们基于来自三项队列研究的肝脏甲基化和表达数据,对73个负责BA稳态和DM的基因进行了系统分析,这些研究包括103例NAFLD患者和75例非NAFLD患者。使用多元线性回归模型,我们在两个NAFLD队列中检测了这些基因转录起始位点附近的甲基化差异,并使用稳健的多元线性回归方法将显著变化的CpG位点的甲基化与第三个队列中的转录表达相关联。
我们检测到64个参与BA稳态和DM的基因存在显著差异甲基化。在其中26个基因中,甲基化与RNA表达显著相关,检测到诸如CYP27A1、OSTɑ和SLC27A5(BA稳态)以及SLCO2B1、SLC47A1以及几个UGT和CYP基因(DM)等基因受NAFLD依赖性调节。
NAFLD与负责BA和DM的关键基因的甲基化显著变化相关,这些变化与转录调节有关。这些发现对BA组成、BA调节的代谢途径以及药物安全性和疗效具有重要意义。